Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003011618> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2003011618 abstract "Background Breast cancer (BC) cutaneous lesions present as local chest wall recurrence or as isolated sites of metastatic disease. The treatment of cutaneous lesions is challenging and includes chest wall resection, local radiation therapy, and/or salvage chemotherapy which is not curative, associated with significant morbidity, and results in overall response rates of 20–30%. Thus, investigation of novel treatment strategies is warranted. This study incorporates multimodality treatment with topical imiquimod, a TLR-7agonist which generates an immune signal similar to that of pathogenic bacteria and Abraxane, a conventional systemic chemotherapy with potential immunostimulatory effects. Combined, these two agents provide local and systemic strategies which are potentially synergistic; and more effective than as single-agents in treating and controlling cutaneous disease. Trial design: A Phase II single arm, non-randomized study. Patients will be sequentially enrolled and receive a maximum of 3 treatment cycles. A treatment cycle consists of topical imiquimod daily to target lesions for 4 days/week for 4 weeks in addition to Abraxane on Days 1, 8, and 15 every 28 days. Toxicity will be evaluated weekly during treatment then monthly for four months. Defined lesions are assessed at baseline and monthly. Skin biopsies are obtained pre and post treatment for histologic analysis and RT-PCR analysis of a 7 IFN-related gene signature previously associated with tumor inhibition. Immunity to BC antigens and serum TGF-β levels are also evaluated. Aims: To evaluate the safety and anti-tumor effects of chemoimmunotherapy with topical imiquimod and Abraxane. Eligibility criteria: Patients with progressive or relapsed BC after standard therapy who 1) have measurable cutaneous metastatic lesions, 2) are at least 7 days from last chemotherapy, 30 days from local radiotherapy and/or systemic steroids, 3) have adequate blood counts and 4) no history of active autoimmune disease. Bisphosphonates, trastuzumab, and/or hormonal therapy is allowed. Statistical methods: Antitumor activity of target lesions will be assessed per modified WHO criteria. Complete response (CR)-complete clearance of lesions; Partial response (PR) ≥ 50% decrease in lesion size; Stable disease (SD) Accrual: 10 patients received treatment with a target accrual of 15. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT3-01-19." @default.
- W2003011618 created "2016-06-24" @default.
- W2003011618 creator A5017180519 @default.
- W2003011618 creator A5027006941 @default.
- W2003011618 creator A5038264061 @default.
- W2003011618 creator A5065386585 @default.
- W2003011618 creator A5085036384 @default.
- W2003011618 date "2011-12-15" @default.
- W2003011618 modified "2023-09-25" @default.
- W2003011618 title "OT3-01-19: Phase II Study of Topical Imiquimod and Weekly Abraxane for the Treatment of Breast Cancer Cutaneous Metastases." @default.
- W2003011618 doi "https://doi.org/10.1158/0008-5472.sabcs11-ot3-01-19" @default.
- W2003011618 hasPublicationYear "2011" @default.
- W2003011618 type Work @default.
- W2003011618 sameAs 2003011618 @default.
- W2003011618 citedByCount "1" @default.
- W2003011618 countsByYear W20030116182020 @default.
- W2003011618 crossrefType "proceedings-article" @default.
- W2003011618 hasAuthorship W2003011618A5017180519 @default.
- W2003011618 hasAuthorship W2003011618A5027006941 @default.
- W2003011618 hasAuthorship W2003011618A5038264061 @default.
- W2003011618 hasAuthorship W2003011618A5065386585 @default.
- W2003011618 hasAuthorship W2003011618A5085036384 @default.
- W2003011618 hasConcept C121608353 @default.
- W2003011618 hasConcept C126322002 @default.
- W2003011618 hasConcept C141071460 @default.
- W2003011618 hasConcept C143998085 @default.
- W2003011618 hasConcept C16005928 @default.
- W2003011618 hasConcept C2776694085 @default.
- W2003011618 hasConcept C2777701055 @default.
- W2003011618 hasConcept C2779112978 @default.
- W2003011618 hasConcept C2780790343 @default.
- W2003011618 hasConcept C2781274730 @default.
- W2003011618 hasConcept C31760486 @default.
- W2003011618 hasConcept C509974204 @default.
- W2003011618 hasConcept C530470458 @default.
- W2003011618 hasConcept C71924100 @default.
- W2003011618 hasConcept C90924648 @default.
- W2003011618 hasConceptScore W2003011618C121608353 @default.
- W2003011618 hasConceptScore W2003011618C126322002 @default.
- W2003011618 hasConceptScore W2003011618C141071460 @default.
- W2003011618 hasConceptScore W2003011618C143998085 @default.
- W2003011618 hasConceptScore W2003011618C16005928 @default.
- W2003011618 hasConceptScore W2003011618C2776694085 @default.
- W2003011618 hasConceptScore W2003011618C2777701055 @default.
- W2003011618 hasConceptScore W2003011618C2779112978 @default.
- W2003011618 hasConceptScore W2003011618C2780790343 @default.
- W2003011618 hasConceptScore W2003011618C2781274730 @default.
- W2003011618 hasConceptScore W2003011618C31760486 @default.
- W2003011618 hasConceptScore W2003011618C509974204 @default.
- W2003011618 hasConceptScore W2003011618C530470458 @default.
- W2003011618 hasConceptScore W2003011618C71924100 @default.
- W2003011618 hasConceptScore W2003011618C90924648 @default.
- W2003011618 hasLocation W20030116181 @default.
- W2003011618 hasOpenAccess W2003011618 @default.
- W2003011618 hasPrimaryLocation W20030116181 @default.
- W2003011618 hasRelatedWork W1972695867 @default.
- W2003011618 hasRelatedWork W2006521968 @default.
- W2003011618 hasRelatedWork W2063790881 @default.
- W2003011618 hasRelatedWork W2090000910 @default.
- W2003011618 hasRelatedWork W2153494864 @default.
- W2003011618 hasRelatedWork W2241042737 @default.
- W2003011618 hasRelatedWork W2261062129 @default.
- W2003011618 hasRelatedWork W2323845137 @default.
- W2003011618 hasRelatedWork W2334682805 @default.
- W2003011618 hasRelatedWork W2335344844 @default.
- W2003011618 hasRelatedWork W2461739654 @default.
- W2003011618 hasRelatedWork W2485285482 @default.
- W2003011618 hasRelatedWork W2567294122 @default.
- W2003011618 hasRelatedWork W2580201242 @default.
- W2003011618 hasRelatedWork W2783703583 @default.
- W2003011618 hasRelatedWork W2790082231 @default.
- W2003011618 hasRelatedWork W2886517663 @default.
- W2003011618 hasRelatedWork W2988414973 @default.
- W2003011618 hasRelatedWork W3042704706 @default.
- W2003011618 hasRelatedWork W34198492 @default.
- W2003011618 isParatext "false" @default.
- W2003011618 isRetracted "false" @default.
- W2003011618 magId "2003011618" @default.
- W2003011618 workType "article" @default.